Idéal Investisseur
Français English
CAC 40 : Market closed
7 847,32 pts
+0.83%


Last updated : 26/10/2026 - 17h35
🏠 Home   ➤    Stock news

Aton: Bcell Design raises €400,000 in convertible bonds to target international markets

In a press release published on October 26, 2026, the Aton group announced that the historical shareholders of Bcell Design had subscribed to an issuance of convertible bonds into shares (OCA) intended to be converted into capital, including interest, with no repayment. Bcell Design is held 12.12% by Inoviem Scientific, itself 96.74% owned by the Aton group.


Aton: Bcell Design raises €400,000 in convertible bonds to target international markets

Funds directed towards prospecting, marketing and international expansion

The €400,000 raised must finance the marketing and commercial deployment of Bcell Design in France and internationally. According to the press release, after financing investment in production tools, historical shareholders are now accompanying "the next stage: marketing and commercial investment".

The funds will be used to develop the customer portfolio, pursue international prospecting and structure commercial activities. They must also enable strengthening of communication and commercial materials, as well as increased presence at major international industry events.

The group indicates that four markets are already subject to initiatives. The stated objective is to "convert ongoing evaluations into orders and recurring supply contracts", to win new industrial clients and to make international markets a growth driver for Bcell Design's revenue.

An industrial tool in place and three revenue streams targeted

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Specialized in monoclonal antibodies, Bcell Design is based at the Strasbourg Innovation Park in Illkirch-Graffenstaden. It relies on three patented technology platforms (GammaPrim, Hamiga and InEps) and on a catalog of 80 monoclonal antibodies covering infectiology, autoimmunity and allergy.

The company can develop the same antibody in multiple isotypes (IgG, IgA, IgM, IgE) and has an ISO 9001 certified production tool. It operates in diagnostics, clinical research and the pharmaceutical industry, and combines three revenue streams: recurring product sales, development contracts and licensing royalties.

"Bcell Design has the means to gain visibility and transform its first commercial successes, in China, Canada and soon in India, into sustainable growth," declared Léone Atayi, Chief Executive Officer of Aton.

Related


Sector Pharmacie et biotechnologies › Biotechnologies


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: T1 2026
Key reported figures
  • Revenue: 287 millions d'euros
  • Quarterly revenue: 287 millions d'euros
Outlook / guidance
  • Management commentary: le Groupe confirme son objectif 2026 de marge d'EBIT ajusté d'environ 10% au second semestre et de génération de free cash-flow de 50 millions d'euros pour l'exercice

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours